"LS 174T[LS174T]人結(jié)腸腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

換液周期：每周2-3次

Rat Lung-65 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：M-07e細(xì)胞、OCI Ly3細(xì)胞、Mv.1.Lu細(xì)胞

HBMEC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LNCaP clone FGC細(xì)胞、U-266 AR1細(xì)胞、LS-174T細(xì)胞

293H Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SMC-1細(xì)胞、HEK (AD293)細(xì)胞、MSB-1細(xì)胞

背景信息：LS １７４T是LS １８０ (AC CL １８７)結(jié)腸腺癌細(xì)胞株的胰蛋白酶化變種。 它比親本更易傳代，象LS １８０一樣生成大量的癌胚抗原(A)。 電鏡研究表明有豐富的微絲和細(xì)胞質(zhì)粘素泡。 直腸抗原３陽性。 p５３抗原表達(dá)陰性，但mRNA表達(dá)陽性。 與AC CL-１８７來源于同一個(gè)腫瘤。LS １７４T細(xì)胞角蛋白染色陽性。 癌基因c-myc, N-myc, H-ras, N-ras, Myb, 和 fos的表達(dá)呈陽性。 癌基因k-ras和sis的表達(dá)未做檢測。

LS 174T[LS174T]人結(jié)腸腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

貼壁細(xì)胞的傳代培養(yǎng)，詳細(xì)步驟如下：首先倒掉培養(yǎng)基，在這一步驟可以收集一些細(xì)胞上清做支原體檢測；加入胰蛋白酶，一般T25是加2mL，蓋好瓶蓋，搖晃T25培養(yǎng)瓶，使胰蛋白酶均勻覆蓋在細(xì)胞表面，放入培養(yǎng)箱2-3min，期間可在顯微鏡下觀察，看到大部分細(xì)胞變圓，即可放入超凈臺，加入2倍的完全培養(yǎng)基，這里就是加4mL培養(yǎng)基，終止消化；將含有胰蛋白酶，細(xì)胞和培養(yǎng)基一起轉(zhuǎn)移到離心管中，1000rpm/3min離心，去掉上清；新鮮的完全培養(yǎng)基重懸，根據(jù)細(xì)胞的生長特性和后續(xù)的實(shí)驗(yàn)需求進(jìn)行傳代，比如我養(yǎng)的Hepa1-6就長的比較快，不是著急用的話，我就會按1E6個(gè)細(xì)胞/T75培養(yǎng)瓶進(jìn)行傳代；但如果后兩天要用，就會適當(dāng)多傳一點(diǎn)；還可通過顯微鏡計(jì)數(shù)后，直接用于細(xì)胞鋪板，繼續(xù)后續(xù)的實(shí)驗(yàn)。

Mia PACA 2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U118細(xì)胞、Ramos 1細(xì)胞、GM06141B細(xì)胞

DMS-79 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U031細(xì)胞、AM38細(xì)胞、UMUC1細(xì)胞

OCI-AML4 Cells;背景說明：急性髓系白血??；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC-94細(xì)胞、F36P細(xì)胞、Colo320細(xì)胞

AP.6 Cells(提供STR鑒定圖譜)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

物種來源：人源、鼠源等其它物種來源

LS 174T[LS174T]人結(jié)腸腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

形態(tài)特性：上皮細(xì)胞樣

貼壁細(xì)胞消化傳代時(shí)通常采用兩種方法：一、加入胰酶等細(xì)胞脫落后，再加培養(yǎng)基中止胰酶作用，離心傳代；二、加入胰酶后，鏡下觀察待細(xì)胞始脫落時(shí)，棄胰酶，加培養(yǎng)分瓶。但前者太麻煩，而后者有可能對細(xì)胞施加胰酶選擇，因?yàn)榭偸琴N壁不牢的細(xì)胞先脫落，對腫瘤細(xì)胞來說，這部分細(xì)胞有可能是惡性程度較GAO的細(xì)胞亞群。一種簡單的消化傳代方法。加入PBS洗去血清或加入胰酶先中和血清的作用(３０s)，棄之，再加入適量胰酶作用１０s-４０s(根據(jù)細(xì)胞消化的難易程度)，棄之，這樣依賴殘余的胰酶就可將細(xì)胞消化單細(xì)胞。對于較難消化的細(xì)胞，可以用２%利多卡因消化５-８分鐘，然后再棄去，加培養(yǎng)基吹打也可以，對細(xì)胞的影響不大。不用PBS也不用Hanks洗，只要把舊培養(yǎng)吸的干凈一點(diǎn)，直接加酶消化應(yīng)該不會有什么問題。棄培養(yǎng)后，用０.０４%的EDA沖洗一次，再用１/４v的０.０４%的EDA室溫孵育５min，棄取大部分EDA，加入與剩余EDA等量的胰酶(預(yù)熱)總體積１/１０v。消化到有細(xì)胞脫落。不過有人說EDA對細(xì)胞不HAO，有證據(jù)嗎？培養(yǎng)的BASMC：倒掉舊培養(yǎng)加入少量胰酶沖一下，倒掉再加入０.１２５-０.２５%胰酶約６-１０滴或１ml(２５ml bole)消化再加入適量新培養(yǎng)基中和，并分瓶這種方法簡單、省事；效果很HAO并且不損失細(xì)胞！

RSC 96 Cells;背景說明：雪旺細(xì)胞；自發(fā)永生;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ej138細(xì)胞、SKMEL-31細(xì)胞、IEC 18細(xì)胞

b.End3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Calu 6細(xì)胞、C1498細(xì)胞、8305-C細(xì)胞

NCI-H2029 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ku812細(xì)胞、P30 OHK細(xì)胞、SK-NEP-1細(xì)胞

A-172 MG Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC-827細(xì)胞、COLO-824細(xì)胞、MEC1細(xì)胞

WM-2664 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Mahlavu細(xì)胞、SNUC2B細(xì)胞、MDCK supertube細(xì)胞

SF-539 Cells;背景說明：膠質(zhì)瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SCCVII細(xì)胞、HCC4006細(xì)胞、UMR 106細(xì)胞

NCI-H187 Cells;背景說明：經(jīng)典小細(xì)胞肺癌；胸腔積液轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RCK8細(xì)胞、Y 1細(xì)胞、HEK-293H細(xì)胞

ROS 17/28 Cells;背景說明：骨肉瘤；ACI ９９３５;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A-427細(xì)胞、BpRcl細(xì)胞、Ly19細(xì)胞

NSC-34 Cells;背景說明：神經(jīng)元;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CMK細(xì)胞、FRhK-4細(xì)胞、SKRC 39細(xì)胞

HBZY-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：OCI-AML-3細(xì)胞、HSC1細(xì)胞、P-388細(xì)胞

H-2405 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：５-１：８傳代;生長特性：混合生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Lu-99A細(xì)胞、WiDr細(xì)胞、WM115F細(xì)胞

Dunn LM8 Cells;背景說明：Dunn's骨肉瘤；雌性；C３H;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：343MG細(xì)胞、Fortner's melanotic melanoma #3細(xì)胞、BMSCs（mBMSCs）細(xì)胞

KYSE-410 Cells;背景說明：食管鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE1細(xì)胞、SKMEL-1細(xì)胞、BTT739細(xì)胞

HCASMC Cells;背景說明：冠狀動脈平滑肌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NR-8383細(xì)胞、J-774細(xì)胞、MA-104細(xì)胞

BNL CL.2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TF1細(xì)胞、JURKAT E-6.1細(xì)胞、Colo-206F細(xì)胞

293-EBNA1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NS-1-Ag4-1細(xì)胞、RAW264.7細(xì)胞、Blotchy fibroblast-11細(xì)胞

NCI-322 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-2171細(xì)胞、H226細(xì)胞、NCI-H460細(xì)胞

Abcam A-549 AKT3 KO Cells(提供STR鑒定圖譜)

Abcam Raji PRG2 KO Cells(提供STR鑒定圖譜)

BayGenomics ES cell line BGA578 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRR812 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTA251 Cells(提供STR鑒定圖譜)

CHCC-OU2 Cells(提供STR鑒定圖譜)

DA01804 Cells(提供STR鑒定圖譜)

ESIBIe003-A-6 Cells(提供STR鑒定圖譜)

GM07249 Cells(提供STR鑒定圖譜)

NCCIT Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４—１：８傳代，每周換液２—３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：L-929細(xì)胞、Ca Ski細(xì)胞、NPC-TW01細(xì)胞

HOEC Cells;背景說明：口腔；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT(H9)細(xì)胞、GDM1細(xì)胞、EA. hy 926細(xì)胞

TC7 Cells;背景說明：結(jié)腸癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KMBC細(xì)胞、LC2/Ad細(xì)胞、A-72細(xì)胞

PAa Cells;背景說明：肺腺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ML2細(xì)胞、HCC2218細(xì)胞、C-8161細(xì)胞

PANC-04-03 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MPC-83細(xì)胞、ADR-RES細(xì)胞、H-II-E-C3細(xì)胞

293/EBNA-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SK_N_FI細(xì)胞、Ly3細(xì)胞、U2-OS細(xì)胞

OV1/P Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CA46細(xì)胞、MDAMB435細(xì)胞、CCD18細(xì)胞

CAL 39 Cells;背景說明：外陰鱗癌細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MM1S細(xì)胞、NCI-H1522細(xì)胞、MMAc.SF細(xì)胞

LS 174T[LS174T]人結(jié)腸腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

REC 1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，２-３天換液１次;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HCC-4006細(xì)胞、U266B1細(xì)胞、HOS (TE85, Clone F5)細(xì)胞

Hs-852-T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：U-343MG細(xì)胞、H-295R細(xì)胞、ACC2細(xì)胞

P3X63 Ag8.653 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Factor Dependent Cell-Paterson 1細(xì)胞、HHL-5細(xì)胞、MDA231-LM2-4175細(xì)胞

NTERA2-D1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TGBC11TKB細(xì)胞、H378細(xì)胞、BT-549細(xì)胞

HEK 293A Cells;背景說明：胚腎；腺病毒包裝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：ESC-410細(xì)胞、LC-1/sq細(xì)胞、RGC5細(xì)胞

SK-GT-4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：6-10B細(xì)胞、H1963細(xì)胞、M2-10B4細(xì)胞

Mel-624 Cells;背景說明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CCK81細(xì)胞、OCI-Ly8細(xì)胞、KYSE-30細(xì)胞

GM11191 Cells(提供STR鑒定圖譜)

HAP1 COPS6 (-) 2 Cells(提供STR鑒定圖譜)

HT Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：WM35細(xì)胞、MIHA細(xì)胞、SNU1細(xì)胞

Me Wo Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代，２-３天換液１次。;生長特性：混合生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：MDAMB453細(xì)胞、SUM 159PT細(xì)胞、SW 1417細(xì)胞

H69/P Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：４傳代，每周換液２次;生長特性：懸浮生長，聚團(tuán);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：Mo 59J細(xì)胞、SNU-1040細(xì)胞、HFT-8810細(xì)胞

QBI-293A Cells;背景說明：胚腎；腺病毒包裝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：G401細(xì)胞、C33-A細(xì)胞、Hs729細(xì)胞

Human ErythroLeukemia Cells;背景說明：這株淋巴母細(xì)胞樣細(xì)胞株，源自一位３０歲白人男性一，患有惡性紅細(xì)胞白血病，能夠自然產(chǎn)生并能誘導(dǎo)球蛋白合成。細(xì)胞的EB病毒核抗原陰性，沒有表面免疫球蛋白與細(xì)胞質(zhì)免疫球蛋白。HEL細(xì)胞表達(dá)HLA抗原(HLA-A３,AW３２,BW３５),β-２小球蛋白，一定比例的細(xì)胞還表達(dá)Ia抗原。這個(gè)細(xì)胞株提供了一種用于研究紅細(xì)胞分化和球蛋白基因表達(dá)的模型。它類似于小鼠中的血友病。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：EBC-1細(xì)胞、LAN6細(xì)胞、GM3570細(xì)胞

SUM102 Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CPAE細(xì)胞、GS9L細(xì)胞、H2.35細(xì)胞

H-2342 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：６傳代 ;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HCT116/L細(xì)胞、LoVo細(xì)胞、H1563細(xì)胞

251MG Cells;背景說明：U-２５１ MG分離至一位患者的膠質(zhì)母細(xì)胞瘤組織。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：Hs-578T細(xì)胞、IMCD-3細(xì)胞、HN 4細(xì)胞

HGADFN188 hTERT Cells(提供STR鑒定圖譜)

IMR-5rPCL20 Cells(提供STR鑒定圖譜)

Lymph8-iPS Cells(提供STR鑒定圖譜)

ND04850 Cells(提供STR鑒定圖譜)

PENN008i-77-5 Cells(提供STR鑒定圖譜)

Ubigene HeLa ATG5 KO Cells(提供STR鑒定圖譜)

WT-ADRC-40 Cells(提供STR鑒定圖譜)

HAP1 TRIM32 (-) 2 Cells(提供STR鑒定圖譜)

3LL Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT-22細(xì)胞、PA-TU S細(xì)胞、SH-SY5Y Parental細(xì)胞

HEK293-FT Cells;背景說明：該細(xì)胞穩(wěn)定表達(dá)SV４０大T抗原，并且促進(jìn)最適病毒產(chǎn)物的產(chǎn)生。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：圓形;相關(guān)產(chǎn)品有：SVEC 4-10細(xì)胞、LM2-4175細(xì)胞、PL12細(xì)胞

Human Pancreatic Duct Epithelial Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：293H細(xì)胞、MDA415細(xì)胞、HPAC細(xì)胞

CHL Cells;背景說明：廣泛應(yīng)用于染色體異常測試。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Panc-03.27細(xì)胞、MALME.3M細(xì)胞、SUDHL-8細(xì)胞

A204 Cells;背景說明：在裸鼠中成瘤。;傳代方法：１：６-１：１０傳代；每周２-３次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HuT 102細(xì)胞、KY-270細(xì)胞、TK10細(xì)胞

A204 Cells;背景說明：在裸鼠中成瘤。;傳代方法：１：６-１：１０傳代；每周２-３次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HuT 102細(xì)胞、KY-270細(xì)胞、TK10細(xì)胞

NCIH1944 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２—３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：KMM1細(xì)胞、H295R-S1細(xì)胞、HCC9204細(xì)胞

HCC-1187 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代，每周換液２—３次;生長特性：混合生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：High 5細(xì)胞、Wistar Institute-38細(xì)胞、OCI-Ly8細(xì)胞

SKLU01 Cells;背景說明：該細(xì)胞系源于一位６０歲的白人女性患者的肺腺癌組織。;傳代方法：１：２傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：WM 239細(xì)胞、MM-1S細(xì)胞、ATDC-5細(xì)胞

OCI/AML-5 Cells;背景說明：急性髓系白血病細(xì)胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EC-GI-10細(xì)胞、253J-Bladder-V細(xì)胞、MHCC97-H細(xì)胞

A 549 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HLEC-SRA 01/04細(xì)胞、MMAc-SF細(xì)胞、MSB1細(xì)胞

A-172 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK Mel 2細(xì)胞、HPAF-2細(xì)胞、KALS-1細(xì)胞

MyLa 2059 Cells;背景說明：皮膚；T淋巴細(xì)胞瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：B16 melanoma細(xì)胞、KYSE 520細(xì)胞、mRTEC細(xì)胞

BMSC/hBMSCs Cells;背景說明：骨髓間充質(zhì)干 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-SNU-398細(xì)胞、H-820細(xì)胞、251MG細(xì)胞

CV-1 in Origin Simian-7 Cells;背景說明：此細(xì)胞株源自CV-１細(xì)胞株，經(jīng)轉(zhuǎn)染起始點(diǎn)缺失的SV４０病毒突變體得到；編碼表達(dá)野生型T抗原，所以該細(xì)胞適合作為需要SV４０T抗原表達(dá)的載體的轉(zhuǎn)染宿主。該細(xì)胞表達(dá)T抗原，允許SV４０病毒的溶解性生長，支持４０℃時(shí)溫度敏感性A２０９病毒的復(fù)制，支持起始區(qū)域缺陷的SV４０突變體的復(fù)制。因含有SV４０病毒的DNA序列，該細(xì)胞需要在２級生物安全柜中操作。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：MCF-7/ADR細(xì)胞、U937細(xì)胞、Vero C1008細(xì)胞

SD-PJEC Cells(提供STR鑒定圖譜)

TYK-nu Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SEG-1細(xì)胞、Mv 1 Lu (NBL-7)細(xì)胞、HTSMC細(xì)胞

U-87MG ATCC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BJ [Human fibroblast]細(xì)胞、SW 1222細(xì)胞、HT-1376細(xì)胞

J774.A1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DMS114細(xì)胞、UMR 106細(xì)胞、RGC-6細(xì)胞

MDA MB 175 VII Cells;背景說明：該細(xì)胞源自一位５４歲患有乳腺導(dǎo)管癌白人女性的胸腔積液。;傳代方法：１：２—１：６傳代，每周換液２—３次;生長特性：松散貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Ontario Cancer Institute-Acute Myeloid Leukemia-5細(xì)胞、H-1623細(xì)胞、TO 175.T細(xì)胞

SRA01/04 (HLE) Cells;背景說明：晶狀體；上皮細(xì)胞；SV４０轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：AMO-1細(xì)胞、SBC3細(xì)胞、3-LL細(xì)胞

HCS-2/8 Cells;背景說明：軟骨肉瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：293 c18細(xì)胞、PVEC細(xì)胞、GM03570細(xì)胞

ETCC007 Cells;背景說明：原位導(dǎo)管癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VP303細(xì)胞、Panc 08.13細(xì)胞、RCS細(xì)胞

HT-144 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：RMC-1細(xì)胞、SU-DH-L5細(xì)胞、Line 522細(xì)胞

LS 174T[LS174T]人結(jié)腸腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

GM05862 Cells;背景說明：胚胎；成纖維；自發(fā)永生；雄性；Swiss albino;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-1404細(xì)胞、Hs695T細(xì)胞、OVCA-433細(xì)胞

CEM-CCRF Cells;背景說明：G.E. Foley 等人建立了類淋巴母細(xì)胞細(xì)胞株CCRF-CEM。 細(xì)胞是１９６４年１１月從一位四歲白人女性急性淋巴細(xì)胞白血病患者的外周血白血球衣中得到。此細(xì)胞系從香港收集而來。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：PLC-8024細(xì)胞、SF 539細(xì)胞、102PT細(xì)胞

SUM-52PE Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GM01232E細(xì)胞、MOLP2細(xì)胞、NCI-H2135細(xì)胞

HR1K Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：JB6 Cl 30-7b細(xì)胞、AMJ2-C8細(xì)胞、MDA-468細(xì)胞

8305C Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：６傳代;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：P3-X63-Ag8-6-5-3細(xì)胞、RMC細(xì)胞、G361細(xì)胞

LC-2 ad Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MLA-144細(xì)胞、NCI H2106細(xì)胞、Jurkat77細(xì)胞

BayGenomics ES cell line CSH344 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRX366 Cells(提供STR鑒定圖譜)

Beta-LG MAb 28 Cells(提供STR鑒定圖譜)

KM2310 Cells(提供STR鑒定圖譜)

PCRP-ZNF830-1C5 Cells(提供STR鑒定圖譜)

OX-115 Cells(提供STR鑒定圖譜)

" "Patent=US4228236

Jakstys M.M., Tom B.H., Kahan B.D.

Process of producing carcinoembryonic antigen.

Patent number US4228236, 14-Oct-1980

PubMed=7370982

Rutzky L.P., Kaye C.I., Siciliano M.J., Chao M., Kahan B.D.

Longitudinal karyotype and genetic signature analysis of cultured human colon adenocarcinoma cell lines LS180 and LS174T.

Cancer Res. 40:1443-1448(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

PubMed=6401685; DOI=10.1007/BF02617989

Halton D.M., Peterson W.D. Jr., Hukku B.

Cell culture quality control by rapid isoenzymatic characterization.

In Vitro 19:16-24(1983)

PubMed=6652615; DOI=10.1016/0165-4608(83)90092-4

Chen T.-R., Hay R.J., Macy M.L.

Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins.

Cancer Genet. Cytogenet. 10:351-362(1983)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3664476

Kuan S.-F., Byrd J.C., Basbaum C.B., Kim Y.S.

Characterization of quantitative mucin variants from a human colon cancer cell line.

Cancer Res. 47:5715-5724(1987)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=3349466

Chantret I., Barbat A., Dussaulx E., Brattain M.G., Zweibaum A.

Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines.

Cancer Res. 48:1936-1942(1988)

PubMed=1999484; DOI=10.1172/JCI115063; PMCID=PMC329898

Bresalier R.S., Niv Y., Byrd J.C., Duh Q.-Y., Toribara N.W., Rockwell R.W., Dahiya R., Kim Y.S.

Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis.

J. Clin. Invest. 87:1037-1045(1991)

PubMed=8422623; DOI=10.1002/1097-0142(19930115)71:2<315::aid-cncr2820710208>3.0.CO;2-B

Tibbetts L.M., Doremus C.M., Tzanakakis G.N., Vezeridis M.P.

Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production.

Cancer 71:315-321(1993)

PubMed=8464898; DOI=10.1073/pnas.90.7.2842; PMCID=PMC46192

Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G., Bodmer W.F.

Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.

Mutations and altered expression of p16INK4 in human cancer.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=8895552; DOI=10.1002/(SICI)1097-0215(19960927)68:1<126::aid-ijc22>3.0.CO;2-8

Suardet L., Li C., Little J.B.

Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.

Int. J. Cancer 68:126-131(1996)

PubMed=9000147

Cottu P.-H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D., Thomas G., Hamelin R.

Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.

Oncogene 13:2727-2730(1996)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::aid-mc5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3

Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.

Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.

Eur. J. Cancer 35:1724-1729(1999)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11226274; DOI=10.1073/pnas.041603298; PMCID=PMC30173

Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D., Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.

Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.

Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11526487; DOI=10.1038/sj.onc.1204611

Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.-H., Hamelin R.

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Oncogene 20:5025-5032(2001)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=12606785; DOI=10.1124/mol.63.3.742

Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A., Marin J.J.G.

Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors.

Mol. Pharmacol. 63:742-750(2003)

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16418264; DOI=10.1073/pnas.0510146103; PMCID=PMC1327731

Liu Y., Bodmer W.F.

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)

PubMed=16854228; DOI=10.1186/1476-4598-5-29; PMCID=PMC1550420

Bandres Elizalde E.M., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.

Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.

Mol. Cancer 5:29.1-29.10(2006)

PubMed=18258742; DOI=10.1073/pnas.0712176105; PMCID=PMC2268141

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

PubMed=19132987; DOI=10.1111/j.1600-0463.2008.01042.x

Li Y.-Q., Tanaka Y., Tada M., Hua R., Seto M., Asaoka Y., Ohta M., Kanai F., Yoshida H., Kawabe T., Sano T., Motojima T., Yokosuka O., Omata M.

Absence of the AKT1 pleckstrin homology domain mutation in Japanese gastrointestinal and liver cancer patients.

APMIS 116:931-933(2008)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Br. J. Cancer 103:340-346(2010)

PubMed=23272949; DOI=10.1186/1755-8794-5-66; PMCID=PMC3543849

Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

BMC Med. Genomics 5:66.1-66.15(2012)

PubMed=24042735; DOI=10.1038/oncsis.2013.35; PMCID=PMC3816225

Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.

Epigenetic and genetic features of 24 colon cancer cell lines.

Oncogenesis 2:e71.1-e71.8(2013)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)

PubMed=24840470; DOI=10.1016/j.jprot.2014.05.002

Chik J.H.L., Zhou J., Moh E.S.X., Christopherson R., Clarke S.J., Molloy M.P., Packer N.H.

Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies.

J. Proteomics 108:146-162(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457

Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Clin. Cancer Res. 21:3695-3704(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235; PMCID=PMC4762531

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)"